CN105193650A - 人参、落叶松提取物制备方法及其在化妆品方面的应用 - Google Patents
人参、落叶松提取物制备方法及其在化妆品方面的应用 Download PDFInfo
- Publication number
- CN105193650A CN105193650A CN201510511057.2A CN201510511057A CN105193650A CN 105193650 A CN105193650 A CN 105193650A CN 201510511057 A CN201510511057 A CN 201510511057A CN 105193650 A CN105193650 A CN 105193650A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix ginseng
- afg
- larix olgensis
- red ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 103
- 241000208340 Araliaceae Species 0.000 title claims abstract description 81
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 79
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 79
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 79
- 241001139304 Larix gmelinii var. olgensis Species 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims description 14
- 238000000034 method Methods 0.000 title abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 241000699670 Mus sp. Species 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000032683 aging Effects 0.000 claims abstract description 20
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000004185 liver Anatomy 0.000 claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 9
- 239000003480 eluent Substances 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 239000012510 hollow fiber Substances 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract 3
- 241000218652 Larix Species 0.000 claims description 58
- 235000005590 Larix decidua Nutrition 0.000 claims description 58
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 21
- 235000020710 ginseng extract Nutrition 0.000 claims description 21
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 18
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 16
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 16
- 229960002591 hydroxyproline Drugs 0.000 claims description 16
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 16
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 claims description 13
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 10
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 10
- 229960003180 glutathione Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 102000016938 Catalase Human genes 0.000 claims description 9
- 108010053835 Catalase Proteins 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 235000003969 glutathione Nutrition 0.000 claims description 5
- 230000003796 beauty Effects 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000005204 segregation Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- -1 arginyl fructosyl glucose Chemical compound 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000037394 skin elasticity Effects 0.000 abstract description 3
- 239000013049 sediment Substances 0.000 abstract 2
- 238000012869 ethanol precipitation Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 240000006409 Acacia auriculiformis Species 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000105 evaporative light scattering detection Methods 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 240000000513 Santalum album Species 0.000 description 3
- 235000008632 Santalum album Nutrition 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002605 anti-dotal effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 241001106462 Ulmus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000235531 Cupressus funebris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000008124 Picea excelsa Nutrition 0.000 description 1
- 244000193463 Picea excelsa Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000011615 Pinus koraiensis Nutrition 0.000 description 1
- 241000114025 Pinus sylvestris var. mongolica Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241001300088 Ulmus macrocarpa Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003722 gum benzoin Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229940072101 nimotop Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种利用人参加工品红参制备含有精氨酸糖苷(AFG)的水提取物的制备方法。红参粉末用高浓度乙醇萃取,离心,过滤,得沉淀,再用水溶解,过滤,滤液乙醇沉淀,乙醇水溶液减压回收乙醇,离心去除沉淀,上清液过阳离子交换树脂,用柠檬酸水溶液洗脱,收集含AFG的洗脱液,过400Da的中空纤维滤膜,取滤膜截留部分,冷冻干燥即得富含AFG的红参提取物。红参水提取物与长白落叶松提取物按一定比例进行混合,其中红参水提取物含有AFG为81-85%,长白落叶松提取物含有二氢槲皮素为90%。动物体内实验表明:红参水提取物配合长白落叶松提取物具有提高衰老小鼠血清中SOD、皮肤中HYP及肝脏中CAT和GSH的水平,具有提高皮肤弹性以及抗衰老的效果;揭示落叶松、红参提取物具有抗炎抗过敏活性。
Description
技术领域
本发明涉及一种以人参、落叶松的提取物的提取工艺,具体说是从人参根中提取精氨酸糖苷并配合长白落叶松木提取物的工艺和它们在化妆品方面的应用。
背景技术
古来木材提取物就被用来制作美容化妆品,例如,檀香木、柏木、香樟木、安息香树脂等。檀香古来便深受欢迎,从印度到埃及、希腊、罗马的贸易路线上,常见蓬车载满着檀香。檀香具有深厚木质香气,通常用于香水和护肤霜,添加檀香精油的肥皂和沐浴露等也是非常受欢迎的。檀香精油本身被作为一种香水或混合其他精油,是一些香水的关键成分,在中国,檀香也有1000多年的使用历史,从古代的皇帝,到今天的上流社会,对檀香都有一种特别的独爱。明代著名医药学家李时珍[1]指出“檀香用于面生黑子,每夜以浆水洗之令赤,磨汁涂之甚良”。但古代对于落叶松木材提取物在医药化妆品方面的应用较少。目前世界各国对于森林资源也包括非木材资源的开发利用都给与足够的重视。美国怀俄明州弗拉维特普雷有限公司在中国申请专利(201280072960.8)“在美容和卫生学产品中使用木材提取物的方法”一文中指出应用落叶松木提取物,尤其是落叶松木材中含有的:抗氧化剂二氢槲皮素(紫杉叶素)以及阿拉伯半乳聚糖用于口腔、皮肤和头发护理等用途。这些落叶松包括兴安落叶松、西伯利亚落叶松等6种落叶松,但未包括长白落叶松。中国专利(201310302501)“长白落叶松提取物的制备方法及医药用途”一文中阐述,利用从人工栽培的长白落叶松采伐的废弃树根提取的提取物,其中主要含有二氢槲皮素应用于化妆品。二氢槲皮素具有多种生物活性,经研究发现,二氢槲皮素具有抗肿瘤[2-4]抗氧化[5-8]抗辐射[9]抗病毒[10,11]抗心血管系统疾病及改善毛细血管微循环、改善脑部血液循环、抗血小板凝聚等作用[12],落叶松中二氢槲皮素对酪氨酸酶的抑制作用[13]。Kwon等自黄榆根分离得到花旗松素-葡萄糖苷,并通过实验表明其可以抑制iNOS(诱生型一氧化氮激酶)表达,具有抗炎作用[14]。于庆海等[15]用大鼠腹腔肥大细胞释放组胺的方法观察了8种黄酮类化合物包括二氢槲皮素对化合物48/80和金霉素等诱导肥大细胞释放组胺的作用,对黄酮类化合物在肥大细胞组胺释放及其在抗变态、抗过敏、抗炎等作用方面提供部分实验数据与解释。
长白山落叶松植被丰富,它伴生着一种传奇的植物—人参。人参属半阴性植物,所以生长期内需自然遮阴,一般是天然针阔混交林,针叶树种有红松、落叶松、樟子松等,阔叶树种有椴树、桦树、柞树、色树、榆树、水桃、黄柏、蜡树、楸树、杨树等天然次生混交林,经过数十年或几百年的生长,形成了举世闻名的瑰宝受到世人的青睐。
人参具有几千年的应用历史,人参(PanaxginsengC.A.Meyer)系五加科(Araliaceae)多年生草本植物——人参的干燥根及根茎,人参是长白山最具开发潜力的药用植物资源之一。在古代,“百草之王”的人参也被称为神草,在现代,人参已是中外闻名、老幼皆可用的名贵中药材。人参作为驰名世界的滋补性药材,具有滋阴、补气、生津、益血、健胃、强心等作用,被誉为扶正固本、滋阴补生之极品。我国历史上《神农本草经》和《本草纲目》等许多部药学名著记载,人参主补五脏、安精神、定魂魄、止惊悸、祛除邪气,利肝明目、益智开心,长期服用可身轻延年。现代医学研究表明,人参具有抗辐射防肿瘤、抗氧化防衰老、耐缺氧增强记忆、调整生理机能和增强机体免疫力、抑制血小板聚集等多种生物学活性。目前,在人参中发现的主要有效物质有人参皂苷、有机酸及酯类、多糖、氨基酸、腺苷、L-焦谷氨酸、维生素类、微量元素等[16]。
化妆品(中华人民共和国卫生部.化妆品卫生规范[S].卫生部卫生法制与监督司编印,2002.)是以涂抹、喷洒等方法直接作用于脸部、手部等人体表面部位,用来清洁皮肤、消除身体的不良异味的日化产品,可起到护肤、美容和治疗的效果。在化妆品中添加天然植物活性成分,不用防腐剂以及其他的化学物质,已被化妆品使用者所接受,因而受到绝大多数消费者的欢迎[17]。因此,开发研究天然活性成分,并将其应用到化妆品中,是当前和未来化妆品产业可持续发展的重要方向之一。
人参皂苷是目前人参中研究最多的活性物质,其具有抗氧化、防紫外线、保
护皮肤等作用[18]。众多研究表明:人参皂苷Rb1、Rb2、Rc、Rd、Re、Rg1、Rg2、Rh1对体内自由基均有不同程度的清除作用。抗氧化活性较强的人参皂苷Rb1,能恢复经户外紫外线(UVB)照射而导致氧化受损的角质细胞,增加其抗氧化酶的活性,可拮抗皮肤老化、促进细胞增殖,具有抗皮肤衰老的作用。但也有很多研究表明人参非皂苷类物质也是人参的主要活性物质之一。如人参中的精氨酸糖苷(AFG),是精氨酸与麦芽糖经过梅拉德反应所生成的产物以红参中的含量为最多[19,20]。该成分能够促进机体微循环,具有降低血糖、抗肥胖及增强免疫力等多项生理作用。AFG具有抗氧化、抑制酪氨酸酶的活性,对色素沉着亦有明显的防治效果[21]。AFG具有抗炎、抗过敏、保湿、改善皮肤质地、减少皱纹、保护人体皮肤细胞的功能。它可以促进皮肤I/IV型胶原蛋白产生和透明质酸生成,促进NO的产生,从而达到延缓皮肤衰老的作用[22]。SOD、CAT、GSH-Px和T-AOC等共同组成了机体活性氧防御系统,机体防御系统的重要组成部分。总抗氧化能力体现了机体的防御能力,并与衰老相关性疾病的发生息息相关,提高总抗氧化能力可有效治疗或延缓衰老[23]。谷胱甘肽含量是衡量衰老的重要指标,其水平高低间接反应其肝脏衰老程度,丙二醛是脂质过氧化产物,也常作为衰老测定指标。
将长白落叶松和长白山人参经过现代科学的处理,进行有机的结合,将会有更加明显的作用。以含有90%二氢槲皮素的长白落叶松提取物和富含AFG人参提取物相配合,进行关于护肤方面研究尚未见文献报告;本专利将揭示人参AFG提取物的方法,并公开长白落叶松木提取物配合红参提取物在护肤方面的作用。
发明内容
本发明公开了含有AFG的红参水提取物的制备方法。本发明揭示了红参水提取物配合长白落叶松提取物具有提高衰老小鼠血清中超氧化物歧化酶(SOD)、皮肤中羟脯氨酸(HYP)及肝脏中过氧化氢酶(CAT)和还原型谷胱甘肽(GSH)的水平。降低氧化应激损伤、保护肝脏和提高皮肤弹性以及抗衰老的效果。揭示落叶松、人参提取物对二甲苯所致小鼠的耳廓肿胀有显著的抑制作用,并能使其恢复到正常水平。揭示红参水提取物配合长白落叶松提取物对2,4-二硝基氯苯(DNCB)诱导小鼠迟发性超敏反应(DTH)具有消除作用。
含有AFG的红参水提取物的制备方法,其特征在于:
红参粉末用高浓度乙醇萃取,离心,过滤,去除上清液,得沉淀,再用水溶解,过滤,去除不溶部分,滤液乙醇沉淀,乙醇水溶液减压回收乙醇,离心去除沉淀,上清液过阳离子交换树脂,用柠檬酸水溶液洗脱,收集各部洗脱液,合并富含AFG成分洗脱液,过400Da的中空纤维滤膜,取滤膜截留部分,冷冻干燥即得富含AFG的红参提取物。
本发明揭示了落叶松、人参提取物具有提高皮肤中羟脯氨酸(HYP)含量水平,具有抗皮肤衰老作用;本发明揭示了落叶松、人参提取物对2,4-二硝基氯苯(DNCB)诱导小鼠迟发性超敏反应(DTH)具有消除作用,说明人参落叶松提取物具有抗炎和抗过敏作用。
因此,长白落叶松、红参提取物在保护皮肤和美容方面有着可观的开发和应用价值。
本发明的积极效果在于:通过本方法制备得到的红参提取物,去除其中人参皂苷和人参多糖类物质,主要含有AFG的红参提取物仍然具有很强的生物活性;将富含AFG的红参提取物配合含90%二氢槲皮素的长白落叶松提取物,提高了皮肤的抗衰老、抗炎和抗过敏作用。
首次公开主要含有AFG的红参水提取物的提取方法;揭示落叶松、人参提取物具有提高皮肤中羟脯氨酸(HYP)含量水平,具有抗皮肤衰老作用;揭示落叶松、人参提取物对2,4-二硝基氯苯(DNCB)诱导小鼠迟发性超敏反应(DTH)具有消除作用,说明人参落叶松提取物具有抗炎和抗过敏作用。
附图说明
图1AFG标准品HPLC-ELSD色谱图
图2富含AFG红参提取物HPLC-ELSD色谱图
实验例1落叶松、人参提取物对衰老小鼠血清、皮肤和肝脏指标的影响
谷胱甘肽含量是衡量衰老的重要指标,其水平高低间接反应其肝脏衰老程度,丙二醛是脂质过氧化产物,也常作为衰老测定指标,其含量随衰老程度增加而增加。D-半乳糖致小鼠亚急性衰老模型方法的优化结果对ICR小鼠进行衰老处理,AFG灌胃处理,考察落叶松、人参提取物的抗衰老能力。
实验材料
试验样品:由实施例4与实施例5方法所得落叶松、人参混合提取物;药物试剂:D-半乳糖(分析纯,上海楷洋生物技术有限公司),氯化钠(化学纯,北京化工厂),超氧化物歧化酶(SOD)及微量还原型谷胱甘肽(GSH)试剂盒购于南京建成生物工程研究所;
仪器
SpectraMaxPlus384连续光谱扫描式酶标仪(美国分子仪器公司),BP211D。
实验动物
SPF级ICR♂小鼠80只,2月龄,购自吉林大学白求恩医学院实验动物中心,许可证号为SCXK-(吉)2014-0003。饲养条件为温度23±2℃,湿度55±5%,所用饲料为普通饲料。
实验方法
将70只雄性ICR小鼠随机分为7组,每组10只,分别命名为空白组、模型组、阳性药组(尼莫同片),红参提取物单独组、落叶松提取物单独组、落叶松提取物和红参提取物混合组1和落叶松提取物和红参提取物混合组2。整个给药周期中除空白组外均每天皮下颈背部注射D-半乳糖500mg/kg使其衰老,本实验小鼠的给药体积(mL)为小鼠体重(g)的0.01倍,给药周期8周。阳性药组给药16mg/kg、红参提取物组给药50mg/kg、落叶松提取物组给药50mg/kg、落叶松提取物和红参提取物混合组1和混合组2分别给药50mg/kg。
表1血清中SOD、皮肤中HYP及肝脏中CAT和GSH的含量变化
注:与空白比较,*P<0.05;**P<0.01;与模型比较##P<0.05
组1:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:0.5,组2:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:1
从表1中可以看出红参提取物单独能够提高衰老小鼠肝脏中过氧化氢酶CAT和提高衰老小鼠皮肤中羟脯氨酸HYP的水平;落叶松提取物单独可以提高衰老小鼠皮肤中羟脯氨酸HYP的含量;落叶松提取物和红参提取物以1:0.5的比例混合能够提高衰老小鼠肝脏中过氧化氢酶CAT、血清中超氧化物歧化酶SOD以及皮肤中羟脯氨酸HYP的含量;落叶松提取物和红参提取物以1:1的比例混合能够提高衰老小鼠血清中SOD、皮肤中HYP及肝脏中CAT和GSH的各项指标。降低氧化应激损伤、保护肝脏和提高皮肤弹性以及抗衰老的效果。
实验例2落叶松、人参提取物抗炎抗过敏作用
利用二甲苯致小鼠耳肿胀法,观察落叶松、人参提取物抗炎作用;利用2,4-二硝基氯苯(DNCB)诱导小鼠迟发性超敏反应(DTH),观察其抗过敏作用。
实验材料试验样品:由实施例4与实施例5方法所得落叶松、人参混合提取物;药物试剂:复方醋酸地塞米松乳炎平,由三九医药股份有限公司生产,批号:1403038H;二甲苯由北京化学工厂有限公司生产,批号:20140809;2,4-二硝基氯苯(DNCB),由长沙晶康新材料科技有限公司生产,批号:20140309JD;4-氨基吡啶(4-AP),由麦卡希试剂有限公司生产,批号:140828002。
实验动物ICR小鼠,体重18-22g,SPF级,购自长春市亿斯实验动物技术有限责任公司,许可证号为SCXK-(吉)2011-0004。饲养条件为温度23±2℃,湿度为55±5%,适应性饲养一周。试验期间自由摄食与饮水,饲料为普通饲料。
实验方法
抗炎活性实验健康ICR种小鼠60只,雌雄各半,体重18-22g随机分为实验组1:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:0.5,给药200mg/kg,组2:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:1,给药200mg/kg(组1、组2分别与0.18g和0.18g凡士林均匀混合)、模型对照组、正常对照组、复方醋酸地塞米松乳膏(皮炎平)阳性对照组(0.2g/kg),每组12只,实验组1、实验组2、阳性组和模型组小鼠分别在右耳前后两面涂二甲苯致炎(0.02ml/只),正常对照组在右耳前后两面涂相同剂量蒸馏水,致炎0.5、1、2小时后分别用相应剂量的药物在右耳涂药,正常对照组和模型对照组同时涂凡士林(0.2g/kg)。4小时后将小鼠颈椎脱臼处死,剪下双耳,用9mm打孔器分别在左右耳相同部位打下圆耳片,在分析天平称重,以两耳片重量差为炎症肿胀度,计算肿胀抑制率。抑制率%=(对照组-给药组)/对照组×100%。
抗过敏活性实验健康ICR种小鼠60只,雌雄各半,体重18-22g,随机分为实验组1:落叶松提取物与红参提取物组成比例为1:0.5,给药200mg/kg,组2:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:1,给药100mg/kg(组1、组2分别与0.18g和0.19g凡士林均匀混合)、正常对照组、复方醋酸地塞米松乳膏(皮炎平)阳性对照组(0.2g/kg),每组12只。用8%硫化钠酒精溶液法[23]背部、腹部脱毛(2cm×3cm),24小时后用5%DNCB(0.05mL/只),涂布于小鼠脱毛后的腹部皮肤致敏,次日强化1次,正常对照组涂布相同剂量蒸馏水。致敏前1天开始于背部脱毛区涂相应药物一次,每天1次,连续给药7天,模型对照组和正常对照组涂布凡士林(0.2g/kg),末次给药40分钟后,用1%DNCB丙酮液(0.02mL/只)涂右耳激发过敏反应,正常对照组涂布相同剂量蒸馏水,24小时后,颈椎脱臼处死小鼠,剪下双耳,用9mm打孔器分别在左右耳相同部位打下圆耳片,在分析天平称重,以两耳片重量差为肿胀度,作为迟发性超敏反应(DTH)强度指标,剖取胸腺、脾脏称重,计算胸腺、脾脏的肿胀指数。
统计学方法采用SPSS13.0统计软件进行统计描述,所得数据用(±s)表示,组间差异用t检验分析,P<0.05有统计意义。
实验结果
落叶松、人参提取物对二甲苯致小鼠耳廓肿胀的影响见表2。造模后模型对照组耳肿胀度增大,与正常对照组比较,差异有非常显著性意义(P<0.01),说明造模成功。各给药组小鼠耳肿胀度与模型对照组比较,差异均有非常显著性意义(P<0.01);且与正常对照组比较,差异均无显著性意义。说明落叶松、人参提取物对二甲苯所致小鼠的耳廓肿胀有显著的抑制作用,并能使其恢复到正常水平。各给药组与阳性对照组比较,差异均无显著性意义,提示落叶松、人参提取物混合组抗炎效果与阳性药效果相当。
表2落叶松、人参提取物对二甲苯致小鼠耳廓肿胀的影响(±s)
组别 | n | 给药剂量(ml/kg) | 耳肿胀度(mg) | 抑制率(%) |
正常对照组 | 12 | 0.2g/kg | 0.30±0.38 | - |
模型对照组 | 12 | 0.2g/kg | 2.39±0.58① | - |
阳性对照组 | 12 | 0.2g/kg | 0.87±0.51② | 65 |
组1 | 12 | 200mg/kg | 1.15±0.39② | 42 |
组2 | 12 | 200mg/kg | 0.61±0.32② | 72 |
注:与正常对照组比较①P<0.01,与模型组对照组比较②P<0.01
组1:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:0.5,组2:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:1
落叶松、人参提取物对DNCB诱导的小鼠DTH的影响见表3。模型对照组与正常对照组比较,差异有显著性或非常显著性意义(P<0.01),说明造模成功;落叶松、人参提取物组与模型对照组比较,差异有显著性意义(P<0.05),且与正常对照组比较,差异均无显著性意义,说明落叶松、人参提取物对DNCB所致小鼠皮肤DTH引起的耳廓肿胀有显著的对抗作用,能使其恢复到正常水平。给药组的脾脏指数和胸腺指数与正常对照组比较,差异无显著性意义,说明落叶松、人参提取物对机体免疫系统无不良影响。
表3落叶松、人参提取物对DNCB诱导小鼠的DTH的影响(±s)
组别 | n | 给药剂量(ml/kg) | 耳肿胀度(mg) | 脾指数(mg/10g) | 胸腺指数(mg/10g) |
正常对照组 | 12 | 0.2g/kg | 0.33±0.27② | 55.34±9.11② | 24.30±8.91① |
模型对照组 | 12 | 0.2g/kg | 1.65±1.02 | 86.77±18.69 | 30.33±6.13 |
阳性对照组 | 12 | 0.2g/kg | 0.43±0.28② | 22.22±1.76② | 14.37±5.29① |
组1 | 12 | 200mg/kg | 0.82±0.20① | 65.40±9.40① | 24.15±5.15① |
组2 | 12 | 200mg/kg | 0.76±0.23② | 63.50±14.22② | 23.98±5.65① |
注:与模型对照组比较,①P<0.05,②P<0.01
组1:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:0.5,组2:落叶松提取物(二氢槲皮素含量90%)与红参提取物(AFG含量85%)组成比例为1:1
讨论
二甲苯所致小鼠耳廓肿胀是常规的急性炎症模型,采用二甲苯刺激小鼠耳廓可在短时间内引起小鼠耳廓充血、水肿等急性炎症表现,此法简单易行,不需特殊的设备,且具有见效快、用药量少的特点,常用于筛选、评价抗炎药物。实验结果表明,落叶松、人参混合提取物具有显著抑制二甲苯所致的小鼠耳廓肿胀程度的作用。
迟发型超敏反应(DTH),是由T淋巴细胞介导的一种超敏反应。在致敏机体接触致敏源后约24小时以上才出现病变,其组织损伤机制是T细胞与抗原结合而活化,释放出多种淋巴因子,导致反应局部组织发生以单个核细胞浸润和细胞变性坏死为特征的局部变态的炎症反应。DTH小鼠胸腺指数和脾脏指数可以从不同侧面反映机体免疫功能。落叶松、人参提取物的抗过敏作用机理可能与影响炎症小鼠的一些细胞因子有关。
本专利揭示落叶松、人参混合提取物皮肤涂布给药能显著对抗二甲苯所致小鼠耳廓肿胀,能明显地抑制2,4-二硝基氯苯(DNCB)所致小鼠DTH;提示落叶松、人参混合提取物具有抗炎、抗过敏作用。
参考文献
[1]石青,王宁,古代中药外用美容探讨,江西中医药,2006,37(1)18-21.
[2]DEVIMA,DASNP.Invitroeffectsofnaturalplantpolypheolsontheproliferationofnormalandabnormalhumanlymphocytesandtheirsecretionsofinterleukin-2[J].CancerLett,1993,69(3):191~196.
[3]KAWAIIS,TOMONOY,KATASEE.EffectofcitrusflavonoidsonHL-60celldifferentiation[J].AntiCancerRes,1999,19(2A):1261~1269.
[4]KANDASWAMIC,PEKINSE,DRZEWIECKIG.Differentialinhibitionofproliferationofhumansquamouscellcarcinomaandembryonicfibroblastlikelungcellsinculturebyplantflavonoids[J].AntiCancerDrugs,1992,3(5):525~530.
[5]MAROZIENEA,KLIUKIENER,SARLQUSKASJ.Inhibitionofphthalocyaninesensilizedphotohemolysisofhumanerythrocytespolyphenolicantioxidants:descriptionofquantitivesstructuer-activityrelationships[J].CancerLett,2000,157(l):39~44.
[6]YUNBS,LEEIK,KIMJP.LipidperoxidationsinhibitoryactivityofsomeconstituentsisolatedfromthestembarkofEucalyptusglobulus[J].ArchPharmRes,2000,23(2):147~150.
[7]HARAGUCHIH,MOCHIDAY,SAKAIS.ProtectionagainstoxidativedamagebydibydroflavonoilsinEngelhardtiachrysolepis[J].BiosciBiotechnolBiochem,1996,60(6):945~948.
[8]NAKAYAMAT,YAMADAM,OSAWAT,Suppressionofactiveoxygen-Inducedcytotoxicitybyflavoids[J].Biochempharmacol,1993,45(l):265~267.
[9]SUGIHARAN,ARAKAWAT,OHNISHIM.Anti-andpro-oxidativeeffectsofflavonoidsonmetal-inducedIipidhydropeioxide-dependentlipidperoxidationinculturedhepatocytesloadedwithalpha-linolenicacid[J].FreeRadicBiolMed,1999,27(11~12):1313~1323.
[10]CHUSC,HSIEHYS,LINJY.Inhibitoryeffectsofflavonoidsonmoloneymarineleukemiavirusreversetranscriptase[J].JNatProd,1992,55(2):179~183.
[11]BIZIAGOSE,CRUNCEJM,PASSAGOTI.EffectofantiviralsubstancesonhepatitisAvirusreplicationinvitro[J].JMedVirol,1987,22(l):57~66.
[12]ALEXANDERN,SHIKOV,OLGAN.Pozharitskaya,InnaMiroshnyk,etal.Nanodispersionsoftaxifolin:Impactofsolid-statepropertiesondissolutionbehavior[J].InternationalJournalofPharmacectics,2009,377:148~152.
[13]付警辉,柴婧,韩佳彤,刘文丛,落叶松中花旗松素对酪氨酸酶的抑制作用,日用化学工业,2014,44(4),218-221.
[14]KwonJH,KimSB,ParkKH,etal.Antioxidativeandanti-inflammatoryeffectsofphenoliccompoundsfromtherootsofUlmusmacrocarpa[J].ArchivesofPharmacalResearch,2011,34(9):1459~1466.
[15]于庆海,吴春福,高大远,徐涛,杨静玉,李绍顺,张永煜,黄酮类化合物对大鼠腹腔肥大细胞组胺释放的作用,沈阳药科大学学报,1995,12(4),273-277.
[16]Wu,J.Y.,Zhong,J.J..Productionofginsenganditsbioactivecomponentsinplantcellculture:Currenttechnologicalandappliedaspects[J].JournalofBiotechnology,1999,68:89-99.
[17]肖昆.中草药化妆品时代的来临[J].日用化学品科学,2008,31(5):10-12.
[18]李丽丹.中草药美白及有效成分的研究进展[J].中国药业,2010,19(20):
82-83。
[19]鄭毅男.薬用人参に含まれる生理活性物质に関する研究[J].愛媛医学(日
本),1994,13:1-7.
[20]Matsuura,Y.,Zheng,Y.N.,Takaku,T.,etal.Isolationandphysiologicalactivities
ofanewaminoacidderivativefromKoreanredginseng[J].JTradMed,1994,
11:256~263.
[21]抗炎症剂、抗衰老剂、一酸化窒素实产生促进剂及び皮肤化妆料,特开
2010-90076.
[22]チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤、並びにこれら
を含有する化粧料、飲食品組成物及び医薬品組成物,特开2012-140376A.
[23]AkikoSatoh,TakakoYokozawa,EunJuCho,etal.Antioxidativeeffectsrelatedto
thepotentialanti-agingpropertiesoftheChineseprescriptionKangen-karyuand
CarthamiFlosinsenescence-acceleratedmice[J].Arch.Gerontol.Geriatr,
2004,39:69-82。
具体实施方式
实施例1富含AFG的长白山红参提取物的制备方法:100g红参粉碎,过60目筛,用高浓度乙醇1000ml于4℃条件下搅拌过夜,离心,过滤,去除上清液,得沉淀,再用水溶解,过滤,滤液乙醇沉淀,乙醇水溶液减压回收乙醇,离心去除沉淀,上清液过阳离子交换树脂,用0.1%柠檬酸水溶液洗脱,收集富含AFG成分洗脱液,过400Da的中空纤维滤膜,取滤膜截留部分,冷冻干燥即得富含AFG的红参提取物1.5g。用HPLC-ELSD方法检测该提取物中AFG含量85%AFG测定图谱见附图1和附图2。
实施例2富含AFG的长白山红参提取物的制备方法
取100g红参粉碎,过60目筛,用高浓度乙醇1000ml于4℃条件下搅拌过夜,离心,过滤,去除上清液,得沉淀,再用水溶解,过滤,滤液乙醇沉淀,乙醇水溶液减压回收乙醇,离心去除沉淀,上清液过阳离子交换树脂,用0.1%醋酸水溶液洗脱,收集各部洗脱液,合并富含AFG成分洗脱液,过400Da的中空纤维滤膜,取滤膜截留部分,冷冻干燥即得富含AFG的红参提取物1.4g,用HPLC-ELSD方法检测该提取物中AFG含量81%,AFG测定图谱见附图1和附图2。
实施例3参照专利201319302501.0方法,简言之取人工种植长白落叶松根部1公斤清洗,去除根皮,切片,粉碎成木屑;酶解物料,加热提取,浓缩,水沉,去除松香沉淀,萃取,浓缩,浓缩液粗结晶135g,再经反复重结晶,干燥,得纯度90%二氢槲皮素的落叶松提取物120g。
实施例4取按实施例1方法处理得长白山红参提取物5g与实施例3处理方法所得落叶松提取物10g,粉碎过120目筛,混合均匀备用。
实施例5取按实施例1方法处理得长白山红参提取物5g与实施例3处理方法所得落叶松提取物5g,粉碎过120目筛,混合均匀备用。
Claims (4)
1.一种人参水提取物的制备方法,其特征在于,红参粉末(60目)用90-99%乙醇4℃条件下搅拌过夜,离心,过滤,去除上清液,得沉淀,再用水溶解,过滤,去除不溶部分,滤液乙醇沉淀,乙醇水溶液减压回收乙醇,离心去除沉淀,上清液过阳离子交换树脂,用0.01-0.3%柠檬酸或醋酸0.01-0.3%水溶液洗脱,收集各部洗脱液,合并富含AFG成分洗脱液,过400Da的中空纤维滤膜,取滤膜截留部分,冷冻干燥即得富含AFG的红参提取物。
2.根据权利要求1所述的人参水提取物,以人参水提取物与长白落叶松提取物按如下比例进行混合,人参提取物为0.5,0.6,0.7,0.8,0.9,1.0,而长白落叶松提取物为1,其中人参水提取物含有AFG为81-85%,长白落叶松提取物含有二氢槲皮素为90%。
3.根据权利要求2所述的人参、落叶松提取物对二甲苯所致小鼠的耳廓肿胀有显著的抑制作用,人参水提取物配合长白落叶松提取物对2,4-二硝基氯苯(DNCB)诱导小鼠迟发性超敏反应(DTH)具有消除作用,可用于制备皮肤美容化妆品。
4.根据权利要求2所述的人参、落叶松提取物具有提高衰老小鼠血清中超氧化物歧化酶(SOD)、皮肤中羟脯氨酸(HYP)及肝脏中过氧化氢酶(CAT)和还原型谷胱甘肽(GSH)的水平,可用于抗衰老保健食品及美容方面应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510511057.2A CN105193650B (zh) | 2015-08-19 | 2015-08-19 | 人参、落叶松提取物制备方法及其在化妆品方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510511057.2A CN105193650B (zh) | 2015-08-19 | 2015-08-19 | 人参、落叶松提取物制备方法及其在化妆品方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105193650A true CN105193650A (zh) | 2015-12-30 |
CN105193650B CN105193650B (zh) | 2020-09-29 |
Family
ID=54941852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510511057.2A Expired - Fee Related CN105193650B (zh) | 2015-08-19 | 2015-08-19 | 人参、落叶松提取物制备方法及其在化妆品方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105193650B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010172A (zh) * | 2018-08-31 | 2018-12-18 | 吉林农业科技学院 | 一种人参活力素护肤品的制备方法 |
CN112679564A (zh) * | 2021-02-02 | 2021-04-20 | 吉林农业大学 | 一种人参特有化合物精氨酸糖苷af的分离纯化新方法 |
CN112724184A (zh) * | 2021-02-02 | 2021-04-30 | 吉林农业大学 | 人参中特有化合物精氨酸双糖苷afg的高效分离制备新方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101239030A (zh) * | 2008-02-03 | 2008-08-13 | 郑毅男 | 红参提取物制备方法及其护肤产品开发 |
CN103951645A (zh) * | 2013-07-18 | 2014-07-30 | 郑毅男 | 长白落叶松提取物的制备方法及医药用途 |
-
2015
- 2015-08-19 CN CN201510511057.2A patent/CN105193650B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101239030A (zh) * | 2008-02-03 | 2008-08-13 | 郑毅男 | 红参提取物制备方法及其护肤产品开发 |
CN103951645A (zh) * | 2013-07-18 | 2014-07-30 | 郑毅男 | 长白落叶松提取物的制备方法及医药用途 |
Non-Patent Citations (3)
Title |
---|
李慧萍: "《人参AFG系列化妆品开发研究》", 《中国优秀硕士学位论文全文数据库》 * |
李慧萍: "人参AFG系列化妆品开发研究", 《中国优秀硕士学位论文全文数据库》 * |
郑毅男: "《红参中新化合物——精氨酸衍生物的分离与结构鉴定》", 《药学学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109010172A (zh) * | 2018-08-31 | 2018-12-18 | 吉林农业科技学院 | 一种人参活力素护肤品的制备方法 |
CN112679564A (zh) * | 2021-02-02 | 2021-04-20 | 吉林农业大学 | 一种人参特有化合物精氨酸糖苷af的分离纯化新方法 |
CN112724184A (zh) * | 2021-02-02 | 2021-04-30 | 吉林农业大学 | 人参中特有化合物精氨酸双糖苷afg的高效分离制备新方法 |
CN112679564B (zh) * | 2021-02-02 | 2021-08-13 | 吉林农业大学 | 一种人参特有化合物精氨酸糖苷af的分离纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105193650B (zh) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102357069A (zh) | 一种天然活性化妆品及其制备方法和用途 | |
CN101292947A (zh) | 一种具有美白作用的护肤品 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN104997883A (zh) | 一种桦褐孔菌树莓刺莓组合物、桦褐孔菌树莓刺莓复合口服液及其制备方法和应用 | |
CN104984074A (zh) | 一种美容护肤制品及其生产方法与应用 | |
CN101972385B (zh) | 虎眼万年青总黄酮的制备方法及在抗肿瘤和抗炎止痛药物中的应用 | |
CN105193650A (zh) | 人参、落叶松提取物制备方法及其在化妆品方面的应用 | |
CN100556429C (zh) | 一种含有葡萄提取物的药物组合物及其制备方法、用途 | |
CN104586700A (zh) | 一种黄荆叶提取物及其制备方法与应用 | |
KR20130039145A (ko) | 인삼 및 톳 추출물을 함유하는 탈모방지 또는 발모촉진용 조성물 | |
CN105831637A (zh) | 一种抗辐射桑杞枣组合物、制备方法及其应用 | |
CN113116801B (zh) | 一种用于改善皮肤亚健康状态的组合物及其制备方法 | |
CN108143657A (zh) | 一种复方中药眼膜液及其制备工艺 | |
CN111643610A (zh) | 一种植物复合液及其制备方法和应用 | |
CN103689708A (zh) | 松花玉竹液饮品 | |
CN105561285A (zh) | 一种土鳖虫生物活性小肽组合物 | |
CN104922295A (zh) | 一种养血、补血的中药组合物 | |
CN105326731A (zh) | 刺梨外用美白乳及其生产工艺 | |
CN103933094A (zh) | 一种杏香兔耳风提取物及其提取方法、应用 | |
CN113101339B (zh) | 治疗慢性肝损伤汤剂及其制备方法和应用 | |
CN106928376A (zh) | 山茱萸多糖的分离方法及其应用 | |
KR101429049B1 (ko) | 홍삼추출물을 주성분으로 하는 피부미용 개선 조성물 | |
CN102885728A (zh) | 一种以金银花总黄酮为主的天然护肤剂原料及其制备方法 | |
CN1240655A (zh) | 西红花养颜茶及其生产方法 | |
CN104523795A (zh) | 鹿茸糖肽组合物在制备耐缺氧药品及保健食品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200929 |